IL6 and lymphoma: We hypothesize that obinutuzumab likely induced immune complex formation, direct release of proinflammatory factors (IL-6 and IL-8), immune-mediated platelet lysis via CD20 antigen presentation, complement activation, IgM depletion, and endothelial exposure post-lymphoma cell clearance, leading to platelet activation, aggregation, and destruction.